<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8703089</journal-id>
<journal-id journal-id-type="pubmed-jr-id">3587</journal-id>
<journal-id journal-id-type="nlm-ta">Epilepsy Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Epilepsy Res.</journal-id>
<journal-title-group>
<journal-title>Epilepsy research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0920-1211</issn>
<issn pub-type="epub">1872-6844</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27875746</article-id>
<article-id pub-id-type="pmc">5321682</article-id>
<article-id pub-id-type="doi">10.1016/j.eplepsyres.2016.11.002</article-id>
<article-id pub-id-type="manuscript">NIHMS831249</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>De novo and inherited <italic>SCN8A</italic> epilepsy mutations detected by gene panel analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Butler</surname>
<given-names>Kameryn M.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>da Silva</surname>
<given-names>Cristina</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shafir</surname>
<given-names>Yuval</given-names>
</name>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weisfeld-Adams</surname>
<given-names>James D.</given-names>
</name>
<xref ref-type="aff" rid="A4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alexander</surname>
<given-names>John J.</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hegde</surname>
<given-names>Madhuri</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Escayg</surname>
<given-names>Andrew</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Department of Human Genetics, Emory University, Atlanta, GA 30322, United States</aff>
<aff id="A2"><label>b</label>EGL Genetic Diagnostics LLC, Decatur, GA 30033, United States</aff>
<aff id="A3"><label>c</label>The Herman and Walter Samuelson Childrenâ€™s Hospital at Sinai, Division of Pediatric Neurology, Baltimore, MD 21209, United States</aff>
<aff id="A4"><label>d</label>Division of Clinical Genetics and Metabolism, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, United States</aff>
<author-notes>
<corresp id="FN1">Corresponding Author: Andrew Escayg, Ph.D., Department of Human Genetics, Emory University, Atlanta, Georgia 30322, <email>aescayg@emory.edu</email>, Phone: 404-712-8328, Fax: 404-727-3949</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>16</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>06</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>1</month>
<year>2018</year>
</pub-date>
<volume>129</volume>
<fpage>17</fpage>
<lpage>25</lpage>
<!--elocation-id from pubmed: 10.1016/j.eplepsyres.2016.11.002-->
<abstract>
<sec id="S1">
<title>Objectives</title>
<p id="P2">To determine the incidence of pathogenic <italic>SCN8A</italic> variants in a cohort of epilepsy patients referred for clinical genetic testing. We also investigated the contribution of <italic>SCN8A</italic> to autism spectrum disorder, intellectual disability, and neuromuscular disorders in individuals referred for clinical genetic testing at the same testing laboratory.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P3">Sequence data from 275 epilepsy panels screened by Emory Genetics Laboratory were reviewed for variants in <italic>SCN8A</italic>. Additional cases with variants in <italic>SCN8A</italic> were ascertained from other testing laboratories. Parental samples were tested for variant segregation and clinical histories were examined. <italic>SCN8A</italic> variants detected from gene panel analyses for autism spectrum disorder, intellectual disability, and neuromuscular disorders were also examined.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P4">Five variants in <italic>SCN8A</italic> were identified in five individuals with epilepsy. Three variants were <italic>de novo</italic>, one was inherited from an affected parent, and one was inherited from an unaffected parent. Four of the individuals have epilepsy and developmental delay/intellectual disability. The remaining individual has a milder epilepsy presentation without cognitive impairment. We also identified an amino acid substitution at an evolutionarily conserved <italic>SCN8A</italic> residue in a patient who was screened on the autism spectrum disorder panel. Additionally, we examined the distribution of pathogenic <italic>SCN8A</italic> variants across the Na<sub>v</sub>1.6 channel and identified four distinct clusters of variants. These clusters are primarily located in regions of the channel that are important for the kinetics of channel inactivation.</p>
</sec>
<sec id="S4">
<title>Conclusions</title>
<p id="P5">Variants in <italic>SCN8A</italic> may be responsible for a spectrum of epilepsies as well as other neurodevelopmental disorders without seizures. The predominant pathogenic mechanism appears to involve disruption of channel inactivation, leading to gain-of-function effects.</p>
</sec>
</abstract>
<kwd-group>
<kwd>
<italic>SCN8A</italic>
</kwd>
<kwd>Sodium channels</kwd>
<kwd>Epilepsy</kwd>
<kwd>Gene panel analysis</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>